rmtОбщая реаниматологияGeneral Reanimatology1813-97792411-7110FSBI "SRIGR" RAMS10.15360/1813-9779-2018-2-35-45rmt-1678Research ArticleОТРАВЛЕНИЯ И ИНТОКСИКАЦИИPOISONINGS AND INTOXICATIONSКлозапин: механизмы токсичности и побочных эффектовClozapine: Mechanisms of Toxicity and Side EffectsБабкинаА. С.BabkinaA. S.

10703, г. Москва, ул. Петровка, д. 25, стр. 2;

117198, г. Москва, ул. Миклухо-Маклая, д. 6

25 Petrovka Str., Build. 2, 107031 Moscow;

6 Miklukho-Maсlaya Str., 117198 Moscow

ГолубевА. М.GolubevA. M.

10703, г. Москва, ул. Петровка, д. 25, стр. 2;

117198, г. Москва, ул. Миклухо-Маклая, д. 6

25 Petrovka Str., Build. 2, 107031 Moscow;

6 Miklukho-Maсlaya Str., 117198 Moscow

СундуковД. В.SundukovD. V.

117198, г. Москва, ул. Миклухо-Маклая, д. 6

6 Miklukho-Maсlaya Str., 117198 Moscow

БашироваА. Р.BashirovaA. R.

117198, г. Москва, ул. Миклухо-Маклая, д. 6

6 Miklukho-Maсlaya Str., 117198 Moscow

ГолубевМ. А.GolubevM. A.

107045, г. Москва, Сретенский тупик, д. 4

4 Sretensky tupik, Moscow 107045

arkadygolubev@mail.ruНИИ общей реаниматологии им. В. А. Неговского, ФНКЦ реаниматологии и реабилитологии; Российский университет дружбы народовРоссияV. A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; Peoples’ Friendship University of RussiaRussian FederationРоссийский университет дружбы народовРоссияPeoples’ Friendship University of RussiaRussian FederationКорпорация «Медицинские электронные данные»РоссияCorporation «Medical electronic data»Russian Federation2018110520181423545Copyright © Бабкина А.С., Голубев А.М., Сундуков Д.В., Баширова А.Р., Голубев М.А., 20182018Бабкина А.С., Голубев А.М., Сундуков Д.В., Баширова А.Р., Голубев М.А.Babkina A.S., Golubev A.M., Sundukov D.V., Bashirova A.R., Golubev M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.reanimatology.com/rmt/article/view/1678

Клозапин – атипичное антипсихотическое средство с доказанной эффективностью, которое широко используется в клинической практике. Однако, его применение сопряжено с высоким риском развития серьезных побочных эффектов. Угрожающие жизни состояния при приеме клозапина могут быть следствием идиосинкразии, острого отравления в результате непреднамеренной передозировки назначенного препарата, суицидального поведения, криминальных действий. В обзоре представили современные данные о механизмах терапевтического и токсического действия клозапина. Описали воздействие клозапина на клеточные рецепторы и ультраклеточные структуры. Рассмотрели роль основных и промежуточных метаболитов данного лекарственного средства в развитии токсических эффектов.

Clozapine is an atypical antipsychotic agent with a confirmed effectiveness which is widely used in the clinical practice. However, its administration is associated with a high risk of serious adverse events. Life-threatening conditions related to administration of clozapine may be a result of idiosyncrasy, acute poisoning resulting from unintentional overdose of the prescribed dug, suicidal behavior, and criminal actions. The review presents current data on the mechanism of therapeutic and toxic effect of clozapine. It describes the effect of clozapine on cell receptors and ultracellular structures. It dwells on the contribution of major and intermediate metabolites of this medicinal agent to the development of toxic effects.

клозапинлекарственный метаболизмострые отравлениякардиотоксичностьагранулоцитозклозапин-индуцированый миокардитclozapinedrug metabolismacute poisoningcardiotoxicityagranulocytosisclozapine-induced myocarditisReferencesТочилов В.А., Кушнир О.Н. Клозапин – препарат выбора для лечения больных с острыми психозами. Социальная и клин. психиатрия. 2011; 21 (2): 37-42.Tochilov V.A., Kushnir O.N. Сlozapine as a first-choice medication in the treatment of patients with acute psychoses. Sotsialnaya i Klinicheskaya Psikhiatriya. 2011; 21 (2): 37-42. [In Russ.]Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 1999; 47 (1): 13–22. DOI: 10.1046/j.1365-2125.1999.00849.x. PMID: 10073734Campbell M., Young P.I., Bateman D.N., Smith J.M., Thomas S.H. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Clin. Pharmacol. 1999; 47 (1): 13–22. DOI: 10.1046/j.1365-2125.1999.00849.x. PMID: 10073734Green A., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C., Posener J., Lee H., Dawson R., Richards C., Cole J.O., Schatzberg A.F. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry. 2000; 157 (6): 982-986. DOI: 10.1176/appi.ajp.157.6.982. PMID: 10831480Green A., Tohen M., Patel J.K., Banov M., DuRand C., Berman I., Chang H., Zarate C., Posener J., Lee H., Dawson R., Richards C., Cole J.O., Schatzberg A.F. Clozapine in the treatment of refractory psychotic mania. Am. J. Psychiatry. 2000; 157 (6): 982-986. DOI: 10.1176/appi.ajp.157.6.982. PMID: 10831480Szota A., Ogłodek E., Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol. Rep. 2013; 65 (2): 279-287. DOI: 10.1016/S1734-1140(13)71004-1. PMID: 23744413Szota A., Ogłodek E., Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol. Rep. 2013; 65 (2): 279-287. DOI: 10.1016/S1734-1140(13)71004-1. PMID: 23744413Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ. Cardiovasc. Toxicol. 2015; 15 (4): 355-365. DOI: 10.1007/s12012-014-9304-9. PMID: 25539628Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF-κβ. Cardiovasc. Toxicol. 2015; 15 (4): 355-365. DOI: 10.1007/s12012-014-9304-9. PMID: 25539628Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity in rats: involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicol. Rep. 2014; 1: 1213-1223. DOI: 10.1016/j.toxrep.2014.11.012. PMID: 28962331Abdel-Wahab B.A., Metwally M.E. Clozapine-induced cardiotoxicity in rats: involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicol. Rep. 2014; 1: 1213-1223. DOI: 10.1016/j.toxrep.2014.11.012. PMID: 28962331Романова О.Л., Сундуков Д.В., Голубев А.М., Бабкина А.С., Голубев М.А. Морфологические изменения в сердце при отравлении клозапином (экспериментальное исследование). Общая реаниматология. 2017; 13 (2): 6-13. DOI: 10.15360/1813-9779-2017-2-6-13Romanova O.L., Sundukov D.V., Golubev A.M., Babkina A.S., Golubev M.A. Morphological changes in the heart with clozapine poisoning (experimental study). Obshchaya Reanimatologiya = General Reanimatology. 2017; 13 (2): 6-13. DOI: 10.15360/1813-9779-2017-2-6-13. [In Russ., In Engl.]Романова О.Л., Сундуков Д.В., Голубев А.М., Благонравов М.Л., Голубев М.А. Характеристика общепатологических процесссов в легких при отравлении клозапином. Общая реаниматология. 2017; 13 (4): 22-29. DOI: 10.15360/1813-9779-2017-4-22-29Romanova O.L., Sundukov D.V., Golubev A.M., Blagonravov M.L., Golubev M.A. Characteristics of general pathological processes in the lungs following clozapine poisoning. Obshchaya Reanimatologiya = General Reanimatology. 2017; 13 (4): 22-29. DOI: 10.15360/1813-9779-2017-4- 22-29. [In Russ., In Engl.]Данилов Д.С. Современный взгляд на историю атипичных антипсихотических средств. Журн. неврол. и психиатрии им. С.С.Корсакова. 2017; 117 (5): 85 – 93. DOI: 10.17116/jnevro20171175185-93. PMID: 28638038Danilov D.S. A current view on the history of atypical antipsychotics. Zhurnal Nevrologii i Psikhiatrii Imeni S.S.Korsakova. 2017; 117 (5): 85 – 93. DOI: 10.17116/jnevro20171175185-93. PMID: 28638038. [In Russ.]Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry. 2007; 18 (1): 39-60. DOI: 10.1177/0957154X07070335. PMID: 17580753Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry. 2007; 18 (1): 39-60. DOI: 10.1177/0957154X07070335. PMID: 17580753Nucifora F.C.Jr., Mihaljevic M., Lee B., Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017; 14 (3): 750-761. DOI: 10.1007/s13311-017-0552-9. PMID: 28653280Nucifora F.C.Jr., Mihaljevic M., Lee B., Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017; 14 (3): 750-761. DOI: 10.1007/s13311-017-0552-9. PMID: 28653280Hippius H. The history of clozapine. Psychopharmacology (Berl.). 1989; 99 Suppl: S3-S5. DOI: 10.1007/BF00442551. PMID: 2682730Hippius H. The history of clozapine. Psychopharmacology (Berl.). 1989; 99 Suppl: S3-S5. DOI: 10.1007/BF00442551. PMID: 2682730Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45 (9): 789-796. DOI: 10.1001/archpsyc.1988.01800330013001. PMID: 3046553Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45 (9): 789-796. DOI: 10.1001/archpsyc.1988.01800330013001. PMID: 3046553Meltzer H.Y., Cola P., Way L., Thompson P.A., Bastani B., Davies M.A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry. 1993; 150 (11): 1630-1638. DOI: 10.1176/ajp.150.11.1630. PMID: 8105705Meltzer H.Y., Cola P., Way L., Thompson P.A., Bastani B., Davies M.A., Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry. 1993; 150 (11): 1630-1638. DOI: 10.1176/ajp.150.11.1630. PMID: 8105705Khan A.A., Ashraf A., Baker D., Al-Omary M.S., Savage L., Ekmejian A., Singh R.S.H., Brienesse S., Majeed T., Gordon T., Drinkwater V., Collins N.J. Clozapine and incidence of myocarditis and sudden death — long term Australian experience. Int. J. Cardiol. 2017; 238: 136-139. DOI: 10.1016/j.ijcard.2017.03.013. PMID: 28343762Khan A.A., Ashraf A., Baker D., Al-Omary M.S., Savage L., Ekmejian A., Singh R.S.H., Brienesse S., Majeed T., Gordon T., Drinkwater V., Collins N.J. Clozapine and incidence of myocarditis and sudden death — long term Australian experience. Int. J. Cardiol. 2017; 238: 136-139. DOI: 10.1016/j.ijcard.2017.03.013. PMID: 28343762Katta N., Balla S., Aggarwal K. Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death. Autops. Case Rep. 2016; 6 (4): 9-13. DOI: 10.4322/acr.2016.054. PMID: 28210568Katta N., Balla S., Aggarwal K. Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death. Autops. Case Rep. 2016; 6 (4): 9-13. DOI: 10.4322/acr.2016.054. PMID: 28210568Acciavatti T., Martinotti G., Corbo M., Cinosi E., Lupi M., Ricci F., Di Scala R., D’Ugo E., De Francesco V., De Caterina R., di Giannantonio M. Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion. J. Psychopharmacol. 2017; 31 (4): 453-460. DOI: 10.1177/0269881116684337. PMID: 28071178Acciavatti T., Martinotti G., Corbo M., Cinosi E., Lupi M., Ricci F., Di Scala R., D’Ugo E., De Francesco V., De Caterina R., di Giannantonio M. Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion. J. Psychopharmacol. 2017; 31 (4): 453-460. DOI: 10.1177/0269881116684337. PMID: 28071178Woloszyn E., Whig N., Trigoboff E., Grace J.J. Cardiac arrest with clozapine and olanzapine: revealing long QT syndrome. Clin. Schizophr. Relat. Psychoses. 2016; Dec. 20. [Epub. ahead of print]. DOI: 10.3371/CSRP. WOWH.112316. PMID: 27996317Woloszyn E., Whig N., Trigoboff E., Grace J.J. Cardiac arrest with clozapine and olanzapine: revealing long QT syndrome. Clin. Schizophr. Relat. Psychoses. 2016; Dec. 20. [Epub. ahead of print]. DOI: 10.3371/CSRP. WOWH.112316. PMID: 27996317Grande I., Pons A., Baeza I., Torras Á., Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum. Psychopharmacol. 2011; 26 (6): 397-403. DOI: 10.1002/hup.1221. PMID: 21826738Grande I., Pons A., Baeza I., Torras Á., Bernardo M. QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. Hum. Psychopharmacol. 2011; 26 (6): 397-403. DOI: 10.1002/hup.1221. PMID: 21826738Lee S.Y., Kim Y.J., Kim K.T., Choe H., Jo S.H. Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br. J. Pharmacol. 2006; 148 (4): 499-509. DOI: 10.1038/sj.bjp.0706744. PMID: 16633353Lee S.Y., Kim Y.J., Kim K.T., Choe H., Jo S.H. Blockade of HERG human K+ channels and IKr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br. J. Pharmacol. 2006; 148 (4): 499-509. DOI: 10.1038/sj.bjp.0706744. PMID: 16633353Shulman M., Jennifer Njoku I., Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013; 104 (2): 175-184. PMID: 23514994Shulman M., Jennifer Njoku I., Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013; 104 (2): 175- 184. PMID: 23514994Hu Q., Zhang C., Zhu S. Fatal multisystem venous thrombosis associated w ith clozapine. J. Clin. Psychopharmacol. 2013; 33 (2): 256-258. DOI: 10.1097/JCP.0b013e318285683b. PMID: 23422385Hu Q., Zhang C., Zhu S. Fatal multisystem venous thrombosis associated w ith clozapine. J. Clin. Psychopharmacol. 2013; 33 (2): 256-258. DOI: 10.1097/JCP.0b013e318285683b. PMID: 23422385Allenet B., Schmidlin S., Genty C., Bosson J.L. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2012; 21 (1): 42-48. DOI: 10.1002/pds.2210. PMID: 22052683Allenet B., Schmidlin S., Genty C., Bosson J.L. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol. Drug Saf. 2012; 21 (1): 42-48. DOI: 10.1002/pds.2210. PMID: 22052683Werring D., Hacking D., Losseff N., Jäger H.R., Walsh M., Foong J. Cerebral venous sinus thrombosis may be associated with clozapine. J. Neuropsychiatry Clin. Neurosci. 2009; 21 (3): 343-345. DOI: 10.1176/jnp.2009.21.3.343a. PMID: 19776318Werring D., Hacking D., Losseff N., Jäger H.R., Walsh M., Foong J. Cerebral venous sinus thrombosis may be associated with clozapine. J. Neuropsychiatry Clin. Neurosci. 2009; 21 (3): 343-345. DOI: 10.1176/jnp.2009.21.3.343a. PMID: 19776318Axelsson S., Hägg S., Eriksson A.C., Lindahl T.L., Whiss P.A. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 2007; 34 (8): 775-780. DOI: 10.1111/j.1440-1681.2007.04650.x. PMID: 17600556Axelsson S., Hägg S., Eriksson A.C., Lindahl T.L., Whiss P.A. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin. Exp. Pharmacol. Physiol. 2007; 34 (8): 775-780. DOI: 10.1111/j.1440-1681.2007.04650.x. PMID: 17600556Swart L.E., Koster K., Torn M., Budde R.P.J., Uijlings R. Clozapine-induced myocarditis. Schizophr. Res. 2016; 174 (1-3): 161-164. DOI: 10.1016/j.schres.2016.04.016. PMID: 27112636Swart L.E., Koster K., Torn M., Budde R.P.J., Uijlings R. Clozapine-induced myocarditis. Schizophr. Res. 2016; 174 (1-3): 161-164. DOI: 10.1016/j.schres.2016.04.016. PMID: 27112636Barry A.R., Windram J.D., Graham M.M. Clozapine-associated myocarditis: case report and literature review. Can. J. Hosp. Pharm. 2015; 68 (5): 427-429. DOI: 10.4212/cjhp.v68i5.1493. PMID: 26478592Barry A.R., Windram J.D., Graham M.M. Clozapine-associated myocarditis: case report and literature review. Can. J. Hosp. Pharm. 2015; 68 (5): 427-429. DOI: 10.4212/cjhp.v68i5.1493. PMID: 26478592Longhi S., Heres S. Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res. Notes. 2017; 10 (1): 338. DOI: 10.1186/s13104-017-2679-5. PMID: 28750684Longhi S., Heres S. Clozapine-induced, dilated cardiomyopathy: a case report. BMC Res. Notes. 2017; 10 (1): 338. DOI: 10.1186/s13104-017- 2679-5. PMID: 28750684West S., Jeffery-Smith A., Brownlee W., Kenedi C. Covert clozapine overdose: Clozapine toxicity in a naive patient. Aust. N.Z. J. Psychiatry. 2013; 47 (12): 1208-1209. DOI: 10.1177/0004867413495926. PMID: 23817859West S., Jeffery-Smith A., Brownlee W., Kenedi C. Covert clozapine overdose: Clozapine toxicity in a naive patient. Aust. N.Z. J. Psychiatry. 2013; 47 (12): 1208-1209. DOI: 10.1177/0004867413495926. PMID: 23817859McElroy S.L., Dessain E.C., Pope H.G.Jr., Cole J.O., Keck P.E.Jr., Frankenberg F.R., Aizley H.G., O’Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 1991; 52 (10): 411-414. PMID: 1938976McElroy S.L., Dessain E.C., Pope H.G.Jr., Cole J.O., Keck P.E.Jr., Frankenberg F.R., Aizley H.G., O’Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry. 1991; 52 (10): 411-414. PMID: 1938976Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem. Neurosci. 2014; 5 (1): 24-29. DOI: 10.1021/cn400189s. PMID: 24219174Seeman P. Clozapine, a fast-off-D2 antipsychotic. ACS Chem. Neurosci. 2014; 5 (1): 24-29. DOI: 10.1021/cn400189s. PMID: 24219174Dziewczapolski G., Menalled L.B., Savino M.T., Mora M., Stefano F.J., Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the «super-off» phenomenon. Mov. Disord. 1997; 12 (2): 159-166. DOI: 10.1002/mds.870120205. PMID: 9087973Dziewczapolski G., Menalled L.B., Savino M.T., Mora M., Stefano F.J., Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the «super-off» phenomenon. Mov. Disord. 1997; 12 (2): 159-166. DOI: 10.1002/mds.870120205. PMID: 9087973Hermann B., Wetzel C.H., Pestel E., Zieglgänsberger W., Holsboer F., Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem. Biophys. Res. Commun. 1996; 225 (3): 957-960. DOI: 10.1006/bbrc.1996.1278. PMID: 8780717Hermann B., Wetzel C.H., Pestel E., Zieglgänsberger W., Holsboer F., Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem. Biophys. Res. Commun. 1996; 225 (3): 957-960. DOI: 10.1006/bbrc.1996.1278. PMID: 8780717Schmid C.L., Streicher J.M., Meltzer H.Y., Bohn L.M. Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a arrestin2-independent activation of akt. Neuropsychopharmacology. 2014; 39 (8): 1902-1913. DOI: 10.1038/npp.2014.38. PMID: 24531562Schmid C.L., Streicher J.M., Meltzer H.Y., Bohn L.M. Clozapine acts as an ag- onist at serotonin 2A receptors to counter MK-801-induced behaviors through a arrestin2-independent activation of akt. Neuropsychopharmacology. 2014; 39 (8): 1902-1913. DOI: 10.1038/npp.2014.38. PMID: 24531562Козлова С.Н. Коморбидность депрессии, тревоги и ишемической болезни сердца (обзор литературы). Часть I1. Психические расстройства в общей медицине. 2012; 3: 44-52.Kozlova S.N. Comorbidity of depression, anxiety and ischemic heart disease (literature review). Part I1. Psikhicheskie Rasstroistva v Obshchei Meditsine. 2012; 3: 44-52. [In Russ.]Humbert-Claude M., Davenas E., Gbahou F., Vincent L., Arrang J.M. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl.). 2012; 220 (1): 225-241. DOI: 10.1007/s00213-011-2471-5. PMID: 21912901Humbert-Claude M., Davenas E., Gbahou F., Vincent L., Arrang J.M. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl.). 2012; 220 (1): 225-241. DOI: 10.1007/s00213-011-2471-5. PMID: 21912901Лужников Е.А. Медицинская токсикология. Национальное руководство. М.: ГЭОТАР-Медиа; 2012: 528–530.Luzhnikov E.A. Medical toxicology. National guide. Moscow: GEOTARMedia; 2012: 528 – 530. [In Russ.]Бонитенко Ю.Ю., Бонитенко Е.Ю., Батоцыренов Б.В. Отравления азалептином. Клиника, диагностика, лечение. Токсикология. 2006; 7 (2): 29–37.Bonitenko Yu.Yu., Bonitenko E.Yu., Batotsyrenov B.V. Poisoning with azaleptin. Clinic, diagnosis, treatment. Toksikologiya. 2006; 7 (2): 29–37. [In Russ.]Guidotti A., Dong E., Tueting P., Grayson D.R. Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice. Prog. Mol. Biol. Transl. Sci. 2014; 128: 89-101. DOI: 10.1016/B978-0-12-800977-2.00004-8. PMID: 25410542Guidotti A., Dong E., Tueting P., Grayson D.R. Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice. Prog. Mol. Biol. Transl. Sci. 2014; 128: 89-101. DOI: 10.1016/B978-0-12-800977- 2.00004-8. PMID: 25410542Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA. 2008; 105 (36): 13614-13619. DOI: 10.1073/pnas.0805493105. PMID: 18757738Dong E., Nelson M., Grayson D.R., Costa E., Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA. 2008; 105 (36): 13614-13619. DOI: 10.1073/pnas.0805493105. PMID: 18757738Dragovic S., Gunness P., Ingelman-Sundberg M., Vermeulen N.P., Commandeur J.N. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab. Dispos. 2013; 41 (3): 651-658. DOI: 10.1124/dmd.112.050484. PMID: 23297297Dragovic S., Gunness P., Ingelman-Sundberg M., Vermeulen N.P., Commandeur J.N. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab. Dispos. 2013; 41 (3): 651-658. DOI: 10.1124/dmd.112.050484. PMID: 23297297Leung J.G., Nelson S., Takala C.R., Gören J.L. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann. Pharmacother. 2014; 48 (6): 801-805. DOI: 10.1177/1060028014526701. PMID: 24619948Leung J.G., Nelson S., Takala C.R., Gören J.L. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann. Pharmacother. 2014; 48 (6): 801-805. DOI: 10.1177/1060028014526701. PMID: 24619948Fang J. Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur. J. Drug Metab. Pharmacokinet. 2000; 25 (2): 109-114. DOI: 10.1007/ BF03190076. PMID: 11112091Fang J. Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur. J. Drug Metab. Pharmacokinet. 2000; 25 (2): 109-114. DOI: 10.1007/ BF03190076. PMID: 11112091Fang J., Coutts R.T., McKenna K.F., Baker G.B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn. Schmiedebergs Arch. Pharmacol. 1998; 358 (5): 592-599. DOI: 10.1007/PL00005298. PMID: 9840430Fang J., Coutts R.T., McKenna K.F., Baker G.B. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn. Schmiedebergs Arch. Pharmacol. 1998; 358 (5): 592-599. DOI: 10.1007/PL00005298. PMID: 9840430Urichuk L., Prior T.I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008; 9 (5): 410-418. DOI: 10.2174/138920008784746373. PMID: 18537577Urichuk L., Prior T.I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008; 9 (5): 410-418. DOI: 10.2174/138920008784746373. PMID: 18537577Regen F., Herzog I., Hahn E., Ruehl C., Le Bret N., Dettling M., Heuser I., Hellmann-Regen J. Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in vitro approach. Toxicol. Appl. Pharmacol. 2017; 316: 10-16. DOI: 10.1016/j.taap. 2016.12.003. PMID: 27939987Regen F., Herzog I., Hahn E., Ruehl C., Le Bret N., Dettling M., Heuser I., Hellmann-Regen J. Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in vitro approach. Toxicol. Appl. Pharmacol. 2017; 316: 10-16. DOI: 10.1016/j.taap. 2016.12.003. PMID: 27939987Williams D.P., O’Donnell C.J., Maggs J.L., Leeder J.S., Uetrecht J., Pirmohamed M., Park B.K. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem. Res. Toxicol. 2003; 16 (10): 1359-1364. DOI: 10.1021/tx034035z. PMID: 14565776Williams D.P., O’Donnell C.J., Maggs J.L., Leeder J.S., Uetrecht J., Pirmohamed M., Park B.K. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem. Res. Toxicol. 2003; 16 (10): 1359-1364. DOI: 10.1021/tx034035z. PMID: 14565776Shad M.U. Clozapine toxicity: a discussion of pharmacokinetic factors. Asian J. Psychiatr. 2008; 1 (2): 47-49. DOI: 10.1016/j.ajp.2008.09.001. PMID: 23050996Shad M.U. Clozapine toxicity: a discussion of pharmacokinetic factors. Asian J. Psychiatr. 2008; 1 (2): 47-49. DOI: 10.1016/j.ajp.2008.09.001. PMID: 23050996Krivoy A., Gaughran F., Weizman A., Breen G., MacCabe J. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int. Clin. Psychopharmacol. 2016; 31 (4): 179-184. DOI: 10.1097/YIC.0000000000000065. PMID: 25563806Krivoy A., Gaughran F., Weizman A., Breen G., MacCabe J. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. Int. Clin. Psychopharmacol. 2016; 31 (4): 179-184. DOI: 10.1097/YIC.0000000000000065. PMID: 25563806Khaldi S., Kornreich C., Choubani Z., Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale. 2008; 34 (6): 618-624. DOI: 10.1016/j.encep.2007.11.007. PMID: 19081460Khaldi S., Kornreich C., Choubani Z., Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. Encephale. 2008; 34 (6): 618-624. DOI: 10.1016/j.encep.2007.11.007. PMID: 19081460Farver D. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert. Opin. Drug Saf. 2003; 2 (1): 21-35. DOI: 10.1517/ 14740338.2.1.21. PMID: 12904122Farver D. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert. Opin. Drug Saf. 2003; 2 (1): 21-35. DOI: 10.1517/1 4740338.2.1.21. PMID: 12904122Elmorsy E., Smith P.A. Bioenergetic disruption of human micro-vascular endothelial cells by antipsychotics. Biochem. Biophys. Res. Commun. 2015; 460 (3): 857-862. DOI: 10.1016/j.bbrc.2015.03.122. PMID: 25824037Elmorsy E., Smith P.A. Bioenergetic disruption of human micro-vascular endothelial cells by antipsychotics. Biochem. Biophys. Res. Commun. 2015; 460 (3): 857-862. DOI: 10.1016/j.bbrc.2015.03.122. PMID: 25824037Pirmohamed M., Park K. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 1997; 7 (2): 139-158. DOI: 10.2165/00023210-199707020-00005. PMID: 23338132Pirmohamed M., Park K. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 1997; 7 (2): 139-158. DOI: 10.2165/00023210-199707020- 00005. PMID: 23338132Girardin F.R., Poncet A., Perrier A., Vernaz N., Pletscher M., Samer C., Lieberman J.A., Villard J. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2018 Jan. 3; [Epub ahead of print]. DOI: 10.1038/s41397-017-0004-2. PMID: 29298994Girardin F.R., Poncet A., Perrier A., Vernaz N., Pletscher M., Samer C., Lieberman J.A., Villard J. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. Pharmacogenomics J. 2018 Jan. 3; [Epub ahead of print]. DOI: 10.1038/s41397-017-0004-2. PMID: 29298994Youssef D.L., Narayanan P., Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas. Psychiatry. 2016; 24 (2): 176-180. DOI: 10.1177/1039856215604480. PMID: 26400457Youssef D.L., Narayanan P., Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas. Psychiatry. 2016; 24 (2): 176-180. DOI: 10.1177/1039856215604480. PMID: 26400457Hatton J.L., Bhat P.K., Gandhi S. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex. Heart Inst. J. 2015; 42 (2): 155-157. DOI: 10.14503/THIJ-13-3633. PMID: 25873829Hatton J.L., Bhat P.K., Gandhi S. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex. Heart Inst. J. 2015; 42 (2): 155-157. DOI: 10.14503/THIJ-13-3633. PMID: 25873829Nemani K.L., Greene M.C., Ulloa M., Vincenzi B., Copeland P.M., Al-Khadari S., Henderson D.C. Clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. Clin. Schizophr. Relat. Psychoses. 2017; Nov. 22. [Epub ahead of print]. DOI: 10.3371/CSRP.KNMG.111717. PMID: 29164928Nemani K.L., Greene M.C., Ulloa M., Vincenzi B., Copeland P.M., Al-Khadari S., Henderson D.C. Clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder. Clin. Schizophr. Relat. Psychoses. 2017; Nov. 22. [Epub ahead of print]. DOI: 10.3371/CSRP.KNMG.111717. PMID: 29164928Hyde N., Dodd S., Venugopal K., Purdie C., Berk M., O’Neil A. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Curr. Drug Saf. 2015; 10 (2): 125-131. DOI: 10.2174/157488631002150515120209. PMID: 25986036Hyde N., Dodd S., Venugopal K., Purdie C., Berk M., O’Neil A. Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Curr. Drug Saf. 2015; 10 (2): 125-131. DOI: 10.2174/157488631002150515120209. PMID: 25986036Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007; 30 (1): 47-57. PMID: 17194170Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007; 30 (1): 47-57. PMID: 17194170Markovic J., Momcilov-Popin T., Mitrovic D., Ivanovic-Kovacevic S., Sekuli S., Stojsic-Milosavljevic A. Clozapine-induced pericarditis. Afr. J. Psychiatry. (Johannesbg). 2011; 14 (3): 236-238. DOI: 10.4314/ajpsy.v14i3.7. PMID: 21863209Markovic J., Momcilov-Popin T., Mitrovic D., Ivanovic-Kovacevic S., Sekuli S., Stojsic-Milosavljevic A. Clozapine-induced pericarditis. Afr. J. Psychiatry. (Johannesbg). 2011; 14 (3): 236-238. DOI: 10.4314/ajpsy.v14i3.7. PMID: 21863209Wehmeier P.M., Heiser P., Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. 2005; 30 (1): 91-96. DOI: 10.1111/j.1365-2710.2004.00616_1.x. PMID: 15659009Wehmeier P.M., Heiser P., Remschmidt H. Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. J. Clin. Pharm. Ther. 2005; 30 (1): 91-96. DOI: 10.1111/j.1365-2710.2004.00616_1.x. PMID: 15659009Kelly D.L., McMahon R.P., Liu F., Love R.C., Wehring H.J., Shim J.C., Warren K.R., Conley R.R. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J. Clin. Psychiatry. 2010; 71 (3): 304-311. DOI: 10.4088/JCP. 08m04718yel. PMID: 20079332Kelly D.L., McMahon R.P., Liu F., Love R.C., Wehring H.J., Shim J.C., Warren K.R., Conley R.R. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J. Clin. Psychiatry. 2010; 71 (3): 304-311. DOI: 10.4088/JCP. 08m04718yel. PMID: 20079332 63. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ. 2002; 166 (9): 1185-1186. PMID: 12000254Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ. 2002; 166 (9): 1185-1186. PMID: 12000254Modai I., Hirschmann S., Rava A., Kurs R., Barak P., Lichtenberg P., Ritsner M. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J. Clin. Psychopharmacol. 2000; 20 (3): 325-327. DOI: 10.1097/00004714-200006000-00006. PMID: 10831019Modai I., Hirschmann S., Rava A., Kurs R., Barak P., Lichtenberg P., Ritsner M. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J. Clin. Psychopharmacol. 2000; 20 (3): 325-327. DOI: 10.1097/00004714-200006000-00006. PMID: 10831019Gioda C.R., de Oliveira Barreto T., Prímola-Gomes T.N., de Lima D.C., Campos P.P., CapettiniLdos S., Lauton-Santos S., Vasconcelos A.C., Coimbra C.C., Lemos V.S., Pesquero J.L., Cruz J.S. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am. J. Physiol. Heart Circ. Physiol. 2010; 298 (6): H2039-H2045. DOI: 10.1152/ajpheart.00820.2009. PMID: 20304817Gioda C.R., de Oliveira Barreto T., Prímola-Gomes T.N., de Lima D.C., Campos P.P., CapettiniLdos S., Lauton-Santos S., Vasconcelos A.C., Coimbra C.C., Lemos V.S., Pesquero J.L., Cruz J.S. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am. J. Physiol. Heart Circ. Physiol. 2010; 298 (6): H2039-H2045. DOI: 10.1152/ajpheart.00820.2009. PMID: 20304817Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996; 16 (5): 403-409. DOI: 10.1097/00004714-199610000-00011. PMID: 8889915Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 1996; 16 (5): 403-409. DOI: 10.1097/00004714-199610000-00011. PMID: 8889915Ronaldson K.J. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs. 2017; 31 (9): 777-795. DOI: 10.1007/s40263-017-0461-9. PMID: 28808933Ronaldson K.J. Cardiovascular disease in clozapine-treated patients: evidence, mechanisms and management. CNS Drugs. 2017; 31 (9): 777-795. DOI: 10.1007/s40263-017-0461-9. PMID: 28808933Wang J.F., Min J.Y., Hampton T.G., Amende I., Yan X., Malek S., Abelmann W.H., Green A.I., Zeind J., Morgan J.P. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol. 2008; 592 (1-3): 123-127. DOI: 10.1016/j.ejphar.2008.06.088. PMID: 18627770Wang J.F., Min J.Y., Hampton T.G., Amende I., Yan X., Malek S., Abelmann W.H., Green A.I., Zeind J., Morgan J.P. Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur. J. Pharmacol. 2008; 592 (1-3): 123-127. DOI: 10.1016/j.ejphar.2008.06.088. PMID: 18627770Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 1999; 20 (1): 29-34. DOI: 10.1016/S0893-133X(98)00047-5. PMID: 9885782Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology. 1999; 20 (1): 29-34. DOI: 10.1016/S0893-133X(98)00047-5. PMID: 9885782Simons M., Downing S.E. Coronary vasoconstriction and catecholamine cardiomyopathy. Am. Heart J. 1985; 109 (2): 297-304. DOI: 10.1016/0002-8703(85)90597-6. PMID: 3966346Simons M., Downing S.E. Coronary vasoconstriction and catecholamine cardiomyopathy. Am. Heart J. 1985; 109 (2): 297-304. DOI: 10.1016/0002-8703(85)90597-6. PMID: 3966346Ishiyama S., Hiroe M., Nishikawa T., Abe S., Shimojo T., Ito H., Ozasa S., Yamakawa K., Matsuzaki M., Mohammed M.U., Nakazawa H., Kasajima T., Marumo F. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997; 95 (2): 489-496. DOI: 10.1161/01.CIR.95.2.489. PMID: 9008468Ishiyama S., Hiroe M., Nishikawa T., Abe S., Shimojo T., Ito H., Ozasa S., Yamakawa K., Matsuzaki M., Mohammed M.U., Nakazawa H., Kasajima T., Marumo F. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997; 95 (2): 489-496. DOI: 10.1161/01.CIR.95.2.489. PMID: 9008468Patel J.J., Lisi P.A., Lathara Z., Lipchik R.J. Clozapine-induced peripheral and pleural fluid eosinophilia. Ann. Pharmacother. 2012; 46 (2): e4. DOI: 10.1345/aph.1Q642. PMID: 22274140Patel J.J., Lisi P.A., Lathara Z., Lipchik R.J. Clozapine-induced peripheral and pleural fluid eosinophilia. Ann. Pharmacother. 2012; 46 (2): e4. DOI: 10.1345/aph.1Q642. PMID: 22274140Krämer I., Rauber-Lüthy C., Kupferschmidt H., Krähenbühl S., Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin. Neuropharmacol. 2010; 33 (5): 230-234. DOI: 10.1097/WNF.0b013e3181f0ec55. PMID: 20689404Krämer I., Rauber-Lüthy C., Kupferschmidt H., Krähenbühl S., Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin. Neuropharmacol. 2010; 33 (5): 230-234. DOI: 10.1097/WNF.0b013e3181f0ec55. PMID: 20689404Kim D.D., White R.F., Barr A.M., Honer W.G., Procyshyn R.M. Clozapine, elevated heart rate and QTc prolongation. J. Psychiatry Neurosci. 2018; 43 (1):71-72. PMID: 29252168Kim D.D., White R.F., Barr A.M., Honer W.G., Procyshyn R.M. Clozapine, elevated heart rate and QTc prolongation. J. Psychiatry Neurosci. 2018; 43 (1):71-72. PMID: 29252168Hägg S., Jönsson A.K., Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert. Opin. Drug Saf. 2009; 8 (5): 537- 547. DOI: 10.1517/14740330903117271. PMID: 19569978Hägg S., Jönsson A.K., Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert. Opin. Drug Saf. 2009; 8 (5): 537-547. DOI: 10.1517/14740330903117271. PMID: 19569978Kortepeter C., Chen M., Knudsen J.F., Dubitsky G.M., Ahmad S.R., Beitz J. Clozapine and venous thromboembolism. Am. J. Psychiatry. 2002; 159 (5): 876-877. DOI: 10.1176/appi.ajp.159.5.876. PMID: 11986154Kortepeter C., Chen M., Knudsen J.F., Dubitsky G.M., Ahmad S.R., Beitz J. Clozapine and venous thromboembolism. Am. J. Psychiatry. 2002; 159 (5): 876-877. DOI: 10.1176/appi.ajp.159.5.876. PMID: 11986154Belova M.V., Ilyashenko K.K., Burykina I.A., Bitkova Y.Y., Luzhnikov Y.A., Khvatov V.B. Impact of oxidative stress on hemorheological parameters in patients with acute poisonings by psychopharmacological agents. Obshchaya Reanimatologiya = General Reanimatology. 2010; 6 (4): 22 – 25. DOI: 10.15360/1813-9779-2010-4-22. [In Russ., In Engl.]Белова М.В., Ильяшенко К.К., Бурыкина И.А., Биткова Е.Е., Лужников Е.А., Хватов В.Б. Влияние окислительного стресса на показатели гемореологии у больных с острыми отравлениями психофармакологическими средствами. Общая реаниматология. 2010; 6 (4): 22 – 25. DOI: 10.15360/1813-9779-2010-4-22Белова М.В., Ильяшенко К.К., Бурыкина И.А., Биткова Е.Е., Лужников Е.А., Хватов В.Б. Влияние окислительного стресса на показатели гемореологии у больных с острыми отравлениями психофармакологическими средствами. Общая реаниматология. 2010; 6 (4): 22 – 25. DOI: 10.15360/1813-9779-2010-4-22

The authors declare that there are no conflicts of interest present.